COMPANY

Arvinas, Inc

HQ: New Haven, CT source · arvinas.com ↗ · New England

FDA-approved therapeutic company Clinical Phase 2

1 open job · last seen Oct 23, 2026 · 10 sources

Arvinas's candidates include ARV-6723, an oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in solid malignancies, and ARV-806, in a Phase 1 monotherapy trial. From company website Source · checked 2026-10-19

Arvinas developed the first FDA-approved PROTAC, a type of heterobifunctional protein degrader therapy. From company website Source · 2026-10-19

Sources for this description (1)

Arvinas's candidates include ARV-6723, an oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in solid malignancies, and ARV-806, in a Phase 1 monotherapy trial.
- “Mechanism of Action: ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in solid malignancies and is Arvinas’ first clinical candidate in the immuno-oncology (IO) space.” https://www.arvinas.com/research-and-development/pipeline/ (2026-10-19)
- “Arvinas plans to complete the ongoing Phase 1 monotherapy dose escalation clinical trial for ARV-806 and seek an out-licensing agreement for any additional clinical trials, including dose expansion or combination clinical trials.” https://www.arvinas.com/research-and-development/pipeline/ (2026-10-19)

Therapeutic area: immuno-oncology

Modality: PROTAC

Product: ARV-6723 ARV-806

Keywords: neurology oncology castration-resistant prostate cancer KRAS G12D Mutation Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) Breast Cancer Prostate Cancer Metastatic ARV-393 ARV-471 ARV-110

Profile checked Oct 10, 2026

1Open jobs 5Trials (company is sponsor)1FDA records (2 yrs)2NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Medicinal Chemistry Project Leader	Remote, Hybrid, New Haven - CT	Oct 2, 2026	Oct 5, 2026

See all 1 job

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
Jul 29, 2026 Trial start Phase 1/Phase 2: A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors source ↗
May 12, 2026 Partnership Partnership / licensing: $85M (upfront, as published), announced May 12, 2026. Source: SEC filing. source ↗
May 1, 2026 FDA FDA New drug/biologic (novel): VEPPANU (vepdegestrant) — NDA219835, May 1, 2026. Applicant at approval: Arvinas Operations, Inc. source ↗
May 29, 2025 Trial start Phase 1/Phase 2: A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation source ↗
Sep 5, 2024 Trial start Phase 1: A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. source ↗
Feb 15, 2023 Trial start Phase 2: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery source ↗
Mar 1, 2019 Trial start Phase 1/Phase 2: Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer source ↗

Upcoming milestones

Nov 30, 2026 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation · NCT07023731
2028-03 (ESTIMATED) · Phase 1 · A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. · NCT06393738
Mar 31, 2031 (ESTIMATED) · Phase 1/Phase 2 · A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors · NCT07749586

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Medicinal Chemistry Project Leader	Remote, Hybrid, New Haven - CT	Oct 2, 2026	Oct 5, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

May 12, 2026 Partnership / licensing: $85M (upfront, as published), announced May 12, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT07023731	A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation	Phase 1/Phase 2	Active, not recruiting	May 29, 2025	Nov 30, 2026 (estimated)
NCT06393738	A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.	Phase 1	Recruiting	Sep 5, 2024	2028-03 (estimated)
NCT07749586	A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Jul 29, 2026	Mar 31, 2031 (estimated)
NCT05549505	A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery	Phase 2	Completed	Feb 15, 2023	Jul 13, 2024 (actual)
NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer	Phase 1/Phase 2	Completed	Mar 1, 2019	Apr 29, 2024 (actual)

FDA records (last 2 years)

May 1, 2026 FDA New drug/biologic (novel): VEPPANU (vepdegestrant) — NDA219835, May 1, 2026. Applicant at approval: Arvinas Operations, Inc. source ↗

NIH awards 2

Annual award amounts. Total $1.1M.

Apr 3, 2017 NIH award 5R44CA203199-02 FY2017: $402,226 awarded for that fiscal year; activity R44 (SBIR); PI TAYLOR, IAN; recipient as written: ARVINAS, INC., NEW HAVEN, CT. Novel Androgen Receptor Degraders to Treat Castration- source ↗
Mar 18, 2016 NIH award 1R44CA203199-01 FY2016: $648,400 awarded for that fiscal year; activity R44 (SBIR); PI TAYLOR, IAN; recipient as written: ARVINAS, INC., NEW HAVEN, CT. Novel Androgen Receptor Degraders to Treat Castration- source ↗

Connect

See your connections at Arvinas on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12